3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Acrocephalosyndactylia
5
Cholangiocarcinoma
4
Neoplasm Metastasis
3
Carcinoma, Transitional Cell
3
Recurrence
2
Urinary Bladder Neoplasms
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Unknown Primary
1
Myeloproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Eosinophilia
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Injections
6
pembrolizumab
5
toripalimab
3
tislelizumab
3
senaparib
3
Bevacizumab
3
sintilimab
2
Technetium
2
Specimen Handling
2
Nivolumab
2
Ipilimumab
2
Fluorodeoxyglucose F18
2
Carboplatin
2
Blood Specimen Collection
2
zimberelimab
1
tumor-cells apoptosis factor, human
1
tazemetostat
1
spartalizumab
1
sacituzumab govitecan
1
rucaparib
1
osimertinib
1
olaparib
1
etoposide phosphate
1
enzalutamide
1
envafolimab
1
cemiplimab
1
cedazuridine
1
atezolizumab
1
WW Domain-Containing Oxidoreductase
1
Ultrasonography, Doppler
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Solid Tumor
×
pemigatinib
×
1 year
×
Clear all
No trials found.